These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 22218480)

  • 21. Considerations in the treatment of relapsing-remitting multiple sclerosis.
    Calabresi PA
    Neurology; 2002 Apr; 58(8 Suppl 4):S10-22. PubMed ID: 11971122
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
    Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interferon beta-1b (Extavia) for multiple sclerosis.
    Med Lett Drugs Ther; 2010 Nov; 52(1350):86-7. PubMed ID: 21045760
    [No Abstract]   [Full Text] [Related]  

  • 24. Peginterferon beta-1a for the treatment of relapsing multiple sclerosis: A case series.
    Hendin BA
    Mult Scler Relat Disord; 2018 Nov; 26():33-36. PubMed ID: 30216756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review.
    McKeage K
    CNS Drugs; 2015 May; 29(5):425-32. PubMed ID: 25906331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Azathioprine and interferon beta-1b treatment in relapsing-remitting multiple sclerosis.
    Milanese C; La Mantia L; Salmaggi A; Caputo D
    J Neurol Neurosurg Psychiatry; 2001 Mar; 70(3):413-4. PubMed ID: 11181879
    [No Abstract]   [Full Text] [Related]  

  • 27. Interferon β-1a for multiple sclerosis: old drug, new clothes.
    Hartung HP
    Lancet Neurol; 2014 Jul; 13(7):638-9. PubMed ID: 24878062
    [No Abstract]   [Full Text] [Related]  

  • 28. The effect of immunomodulatory treatment on multiple sclerosis fatigue.
    Metz LM; Patten SB; Archibald CJ; Bakker JI; Harris CJ; Patry DG; Bell RB; Yeung M; Murphy WF; Stoian CA; Billesberger K; Tillotson L; Peters S; McGowan D
    J Neurol Neurosurg Psychiatry; 2004 Jul; 75(7):1045-7. PubMed ID: 15201369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis.
    Fusco C; Andreone V; Coppola G; Luongo V; Guerini F; Pace E; Florio C; Pirozzi G; Lanzillo R; Ferrante P; Vivo P; Mini M; Macrì M; Orefice G; Lombardi ML
    Neurology; 2001 Dec; 57(11):1976-9. PubMed ID: 11739812
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Glatiramer acetate in interferon beta non respondent relapsing-remitting multiple sclerosis].
    Oreja-Guevara C; Bermejo PE; Miralles A; Gabaldón L; Aguilar MJ; Díez-Tejedor E
    Neurologia; 2009 Sep; 24(7):435-8. PubMed ID: 19921551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
    Hauser SL; Bar-Or A; Comi G; Giovannoni G; Hartung HP; Hemmer B; Lublin F; Montalban X; Rammohan KW; Selmaj K; Traboulsee A; Wolinsky JS; Arnold DL; Klingelschmitt G; Masterman D; Fontoura P; Belachew S; Chin P; Mairon N; Garren H; Kappos L;
    N Engl J Med; 2017 Jan; 376(3):221-234. PubMed ID: 28002679
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
    Nikfar S; Rahimi R; Abdollahi M
    Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
    Gasperini C; Paolillo A; Giugni E; Galgani S; Bagnato F; Mainero C; Onesti E; Bastianello S; Pozzilli C
    Mult Scler; 2002 Apr; 8(2):119-23. PubMed ID: 11990868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
    Calabresi PA; Kieseier BC; Arnold DL; Balcer LJ; Boyko A; Pelletier J; Liu S; Zhu Y; Seddighzadeh A; Hung S; Deykin A;
    Lancet Neurol; 2014 Jul; 13(7):657-65. PubMed ID: 24794721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Emerging new therapies for relapsing remitting multiple sclerosis].
    Anis S; Achiron A
    Harefuah; 2014 Nov; 153(11):658-62, 687, 686. PubMed ID: 25563027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Birth outcomes in newborns fathered by men with multiple sclerosis exposed to disease-modifying drugs.
    Lu E; Zhu F; Zhao Y; van der Kop M; Synnes A; Dahlgren L; Sadovnick AD; Traboulsee A; Tremlett H
    CNS Drugs; 2014 May; 28(5):475-82. PubMed ID: 24643915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis.
    Chitnis T; Arnold DL; Banwell B; Brück W; Ghezzi A; Giovannoni G; Greenberg B; Krupp L; Rostásy K; Tardieu M; Waubant E; Wolinsky JS; Bar-Or A; Stites T; Chen Y; Putzki N; Merschhemke M; Gärtner J;
    N Engl J Med; 2018 Sep; 379(11):1017-1027. PubMed ID: 30207920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience.
    D'Amico E; Patti F; Zanghì A; Lo Fermo S; Chisari CG; Zappia M
    Expert Rev Clin Pharmacol; 2018 May; 11(5):531-536. PubMed ID: 29521113
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute demyelinating disease after interferon beta-1a treatment for multiple sclerosis.
    Von Raison F; Abboud H; Saint Val C; Brugières P; Césaro P
    Neurology; 2000 Nov; 55(9):1416-7. PubMed ID: 11087800
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.